BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 31255741)

  • 1. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
    Johnson SW; Brown SV; Priest DH
    Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients.
    Scardina TL; Kang Martinez E; Balasubramanian N; Fox-Geiman M; Smith SE; Parada JP
    Pharmacotherapy; 2017 Apr; 37(4):420-428. PubMed ID: 28226419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Vancomycin as Secondary Prophylaxis for
    Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
    Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
    Willems L; Porcher R; Lafaurie M; Casin I; Robin M; Xhaard A; Andreoli AL; Rodriguez-Otero P; Dhedin N; Socié G; Ribaud P; Peffault de Latour R
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1295-301. PubMed ID: 22387347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vancomycin prophylaxis for the prevention of
    Babar S; El Kurdi B; El Iskandarani M; Haddad I; Imam Z; Alomari M; Myers J; Moorman J
    Infect Control Hosp Epidemiol; 2020 Nov; 41(11):1302-1309. PubMed ID: 32594929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
    Knight EM; Schiller DS; Fulman MK; Rastogi R
    J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study.
    Blumberg EA; Collins G; Young JH; Nguyen MH; Michonneau D; Temesgen Z; Origȕen J; Barcan L; Obeid KM; Belloso WH; Gras J; Corbelli GM; Neaton JD; Lundgren J; Snydman DR; Molina JM;
    Transpl Infect Dis; 2022 Feb; 24(1):e13770. PubMed ID: 34821423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral vancomycin for Clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant.
    Altemeier OJ; Konrardy KT
    Transpl Infect Dis; 2022 Apr; 24(2):e13790. PubMed ID: 35014136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
    Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
    Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
    Ganetsky A; Han JH; Hughes ME; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Luger SM; Mangan JK; Martin ME; Smith J; Freyer CW; Gilmar C; Schuster M; Stadtmauer EA; Porter DL
    Clin Infect Dis; 2019 May; 68(12):2003-2009. PubMed ID: 30256954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
    Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
    Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
    Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of
    Maraolo AE; Mazzitelli M; Zappulo E; Scotto R; Granata G; Andini R; Durante-Mangoni E; Petrosillo N; Gentile I
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
    Prohaska L; Mahmoudjafari Z; Shune L; Singh A; Lin T; Abhyankar S; Ganguly S; Grauer D; McGuirk J; Clough L
    Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):233-240. PubMed ID: 29928848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.
    Kamboj M; Xiao K; Kaltsas A; Huang YT; Sun J; Chung D; Wu S; Sheahan A; Sepkowitz K; Jakubowski AA; Papanicolaou G
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1626-33. PubMed ID: 24973628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridioides difficile colonization and infection in patients admitted for a first autologous transplantation: Incidence, risk factors, and patient outcomes.
    Ford CD; Lopansri BK; Coombs J; Webb BJ; Nguyen A; Asch J; Hoda D
    Clin Transplant; 2019 Nov; 33(11):e13712. PubMed ID: 31532030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
    Brown CC; Manis MM; Bohm NM; Curry SR
    Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.